Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101
Two More Health Care SPACs Also Went Public
Executive Summary
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.
You may also be interested in...
Finance Watch: Public Markets Open Back Up For Biopharma Offerings
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
Bluebird CFO Leaves The Nest As Company Reveals Grim Cash Position
Its Q4 earnings report was not the first time that bluebird mentioned selling priority review vouchers it has not received yet, but the PRV revenue is needed to fund operations beyond 2022.
Evotec Adds To Spate Of Metabolic Deals With Lilly Collaboration
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.